Structural Bioinformatics Delivers Lead Compound To BioChem Pharma | GenomeWeb

SAN DIEGO--Privately held Structural Bioinformatics here announced that BioChem Pharma, a Canadian biopharmaceutical company, has accepted a lead compound for the treatment of a human viral infectious disease, triggering a milestone payment in the company's collaboration with BioChem Pharma.

Structural Bioinformatics began collaborating with BioChem in August 1997 to find leads for certain viral and cancer targets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.